FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386023911> ?p ?o ?g. }

• W4386023911 endingPage "e96146ca" @default.
• W4386023911 startingPage "e96146ca" @default.
• W4386023911 abstract "Background: High-dose cytarabine (HDAC) is commonly administered as consolidation therapy to adult patients with newly diagnosed acute myeloid leukemia (AML) achieving complete remission (CR). Compared with alternate day HDAC-135 dosing (given on days 1,3 and 5), condensed regimens such as HDAC-123 (given consecutively for 3 days) are associated with faster hematological recovery, reduced infection rates and shorter periods of hospital stay without impacting survival in adults up to 60 years. However, data is lacking on the use of HDAC-123 in older patients with AML. Aims: We report our experience with a condensed HDAC-123 consolidation regimen as post-remission therapy with the goal of assessing feasibility in AML, including patients >60 years. We hypothesized that HDAC-123 would be an appropriate alternative consolidation option for patients otherwise fit to receive HDAC-135 therapy. Methods: All patients with newly diagnosed AML in first CR who received 1-3 cycles of HDAC-123 consolidation at The Royal Melbourne Hospital and Peter MacCallum Cancer Centre were included in the study if at least one cycle of intensive induction chemotherapy was delivered. Patients were stratified by age (>60 years or ≤60 years). HDAC 1-3 g/m2 twice daily was administered as an inpatient on days 1, 2 and 3 of each 28-day consolidation cycle. Prophylactic granulocyte colony-stimulating factor was given after completing chemotherapy to all patients within each treatment cycle. The primary endpoints were deliverability (average dose per cycle), tolerability (time to hematological recovery), resource utilization (length of hospitalization) and safety (cytarabine-induced fever, neurotoxicity, bacteremia intensive care unit [ICU] admission or early death). Results: From December 2020 to December 2022, 37 patients received HDAC-123: 12 (32%) were >60 years of age and 25 (68%) were ≤60 years. Median age at diagnosis was 67 years if >60 years and 41 years if ≤60 years. There were no significant differences between the age groups with respect to demographics or disease characteristics (Table 1). The average cytarabine dose was 12 g/m2 per cycle (range 6-18 g/m2) in the >60-year cohort and 16.4 g/m2 per cycle in the ≤60-year group (range 6-18 g/m2). Across all 3 cycles, median times to neutrophil and platelet count recovery were 15 and 23 days, respectively (Table 2). In the whole cohort, median duration of hospital stay for chemotherapy administration was 4 days while that for neutropenic monitoring was 9 days. No significant differences in tolerability or resource utilization were seen between the two arms except a reduced median time to neutrophil count recovery after cycle 1 in the ≤60 years arm (14 vs 17 days, P = 0.001). From a safety perspective, cytarabine-induced fever and bacteraemia were most frequently seen during cycle 1 (Table 3). Only 3 patients (8%), all ≤60 years old, required a change in dosing schedule: two (5%) due to renal impairment and one due to reversible cerebellar neurotoxicity. Early mortality rates were low and the overall incidence of adverse events was not significantly different between the two arms. Summary/Conclusion: HDAC-123 is well-tolerated and can be safely delivered to fit AML patients aged >60 years. The associated faster haematological recovery can lead to tangible reductions in hospitalisation periods. Larger prospective and randomised studies are required to confirm our findings and further refine the approach to post-remission therapy in this population.Keywords: Consolidation, AML, Cytarabine" @default.
• W4386023911 created "2023-08-22" @default.
• W4386023911 creator A5005591514 @default.
• W4386023911 creator A5017442411 @default.
• W4386023911 creator A5065977323 @default.
• W4386023911 creator A5071772643 @default.
• W4386023911 date "2023-08-01" @default.
• W4386023911 modified "2023-09-26" @default.
• W4386023911 title "P543: CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA" @default.
• W4386023911 doi "https://doi.org/10.1097/01.hs9.0000969080.96146.ca" @default.
• W4386023911 hasPublicationYear "2023" @default.
• W4386023911 type Work @default.
• W4386023911 citedByCount "0" @default.
• W4386023911 crossrefType "journal-article" @default.
• W4386023911 hasAuthorship W4386023911A5005591514 @default.
• W4386023911 hasAuthorship W4386023911A5017442411 @default.
• W4386023911 hasAuthorship W4386023911A5065977323 @default.
• W4386023911 hasAuthorship W4386023911A5071772643 @default.
• W4386023911 hasBestOaLocation W43860239111 @default.
• W4386023911 hasConcept C126322002 @default.
• W4386023911 hasConcept C141071460 @default.
• W4386023911 hasConcept C143998085 @default.
• W4386023911 hasConcept C197934379 @default.
• W4386023911 hasConcept C2776694085 @default.
• W4386023911 hasConcept C2777288759 @default.
• W4386023911 hasConcept C2778041864 @default.
• W4386023911 hasConcept C2778375690 @default.
• W4386023911 hasConcept C2778461978 @default.
• W4386023911 hasConcept C2778729363 @default.
• W4386023911 hasConcept C2779282312 @default.
• W4386023911 hasConcept C2781413609 @default.
• W4386023911 hasConcept C71924100 @default.
• W4386023911 hasConceptScore W4386023911C126322002 @default.
• W4386023911 hasConceptScore W4386023911C141071460 @default.
• W4386023911 hasConceptScore W4386023911C143998085 @default.
• W4386023911 hasConceptScore W4386023911C197934379 @default.
• W4386023911 hasConceptScore W4386023911C2776694085 @default.
• W4386023911 hasConceptScore W4386023911C2777288759 @default.
• W4386023911 hasConceptScore W4386023911C2778041864 @default.
• W4386023911 hasConceptScore W4386023911C2778375690 @default.
• W4386023911 hasConceptScore W4386023911C2778461978 @default.
• W4386023911 hasConceptScore W4386023911C2778729363 @default.
• W4386023911 hasConceptScore W4386023911C2779282312 @default.
• W4386023911 hasConceptScore W4386023911C2781413609 @default.
• W4386023911 hasConceptScore W4386023911C71924100 @default.
• W4386023911 hasIssue "S3" @default.
• W4386023911 hasLocation W43860239111 @default.
• W4386023911 hasOpenAccess W4386023911 @default.
• W4386023911 hasPrimaryLocation W43860239111 @default.
• W4386023911 hasRelatedWork W2048294528 @default.
• W4386023911 hasRelatedWork W2060644115 @default.
• W4386023911 hasRelatedWork W2073730465 @default.
• W4386023911 hasRelatedWork W2186865501 @default.
• W4386023911 hasRelatedWork W2294565310 @default.
• W4386023911 hasRelatedWork W2897662838 @default.
• W4386023911 hasRelatedWork W2923695651 @default.
• W4386023911 hasRelatedWork W2988852042 @default.
• W4386023911 hasRelatedWork W4232561854 @default.
• W4386023911 hasRelatedWork W4247120321 @default.
• W4386023911 hasVolume "7" @default.
• W4386023911 isParatext "false" @default.
• W4386023911 isRetracted "false" @default.
• W4386023911 workType "article" @default.